Aviation Medication Transparency Act of 2025
- Bill Number
- S. 3258
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Transportation and Public Works
- Status
- Introduced
- Latest Action
- 2025-11-20: Read twice and referred to the Committee on Commerce, Science, and Transportation.
- Last Updated
- 2026-02-11T12:03:25Z
AI-Generated Summary
Purpose
The Aviation Medication Transparency Act of 2025 aims to increase transparency in aviation medical certifications by requiring the Federal Aviation Administration (FAA) to publicly share information on medications that are safe for pilots (airmen) and air traffic control specialists. This ensures these individuals, including those in training, can easily access user-friendly details about approved medications to support their health and certification processes without compromising flight safety.
Key Provisions
- Publication Requirement: Within one year of enactment, the FAA Administrator must publish and maintain on the FAA's public website a comprehensive list of medications deemed safe and approved for treating certain conditions in applicants for medical certification.
- Consultation Process: The list must be developed in consultation with key groups, including the Aeromedical Innovation and Modernization Working Group (a FAA advisory body), accredited aviation education institutions, unions representing air traffic controllers and airline pilots, and other relevant stakeholders.
- Content Details:
- Covers all approved medications, including prescription and over-the-counter (OTC) options.
- Includes a "Do Not Issue" list for prohibited medications.
- Provides guidance on stabilization periods (time needed to adjust to a medication before resuming duties).
- Explains allowable or prohibited uses, conditions treated, and reasons for FAA decisions.
- Offers contact information for doctors and medical providers to ask questions about the list.
- Accessibility and Updates: The list must be presented in a clear, easy-to-understand format and provided to individuals when they first apply for medical certification. It requires annual updates to reflect new determinations.
Significant Changes to Existing Law
This bill introduces a new mandate for the FAA to create, publish, and regularly update a centralized, public list of approved and prohibited medications specifically for aviation medical certifications. Previously, such information may have been compiled internally but was not required to be publicly accessible or shared in a standardized, user-friendly way. It builds on existing FAA authority under aviation safety laws (e.g., referencing the FAA Reauthorization Act of 2024) by emphasizing transparency and stakeholder input, without altering core certification standards.
Potential Impacts
- Government Agencies: The FAA will face additional administrative responsibilities, including consultation, website maintenance, and annual reviews, potentially increasing workload and costs but improving operational efficiency through better-informed applicants.
- Citizens: Pilots, air traffic controllers, and trainees will benefit from clearer guidance on medications, reducing uncertainty in healthcare decisions and potentially speeding up certification processes. Medical providers gain a direct line to FAA for clarifications, enhancing patient care in aviation contexts.
- International Relations: No direct impacts, as the bill focuses on domestic U.S. aviation regulations without addressing foreign carriers or global standards.
Main Stakeholders Affected
- Airmen and Air Traffic Control Specialists: Primary beneficiaries, gaining access to medication information to maintain health and certifications.
- Trainees and Applicants: Individuals pursuing aviation careers who need early guidance on medical requirements.
- Medical Providers and Doctors: Affected through required contact mechanisms and the need to align prescriptions with FAA rules.
- FAA and Government Bodies: Responsible for implementation, including the Aeromedical Working Group.
- Unions and Organizations: Air traffic controller and pilot representatives involved in consultations, ensuring their members' input shapes the list.
- Aviation Education Institutions: Accredited schools contribute expertise to make the list practical for students.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens FAA's existing regulatory framework under Title 49 of the U.S. Code by mandating public disclosure, promoting accountability without overriding medical privacy laws (e.g., HIPAA). It could reduce litigation risks from certification denials by clarifying medication rules upfront.
- Constitutional: No apparent conflicts; the bill aligns with Congress's authority to regulate interstate commerce and aviation safety under the Commerce Clause.
- Political: Bipartisan sponsorship (from Senators Duckworth, Hoeven, Durbin, and Britt) suggests broad support for aviation safety enhancements. It addresses industry calls for modernization, potentially influencing future FAA reauthorizations by demonstrating proactive transparency measures.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Sen. Hoeven, John [R-ND], Sen. Durbin, Richard J. [D-IL], Sen. Britt, Katie Boyd [R-AL], Sen. Hickenlooper, John W. [D-CO], Sen. Risch, James E. [R-ID]
Recent Actions
- 2025-11-20: Read twice and referred to the Committee on Commerce, Science, and Transportation.
- 2025-11-20: Introduced in Senate
Bill Versions
- Aviation Medication Transparency Act of 2025 — issued 2025-11-20 — PDF (5 pages)